Literature DB >> 15351870

[Ulcus terebrans. Therapy options and their limits].

M Sonntag1, J Reifenberger, M Megahed, K W Schulte.   

Abstract

Basal cell carcinoma (BCC) is the most common tumor in humans and is defined as a slow-growing, locally invasive, epithelial skin tumor which rarely metastasizes. The first line treatment is surgical excision with histologic examination of the tumor margins, but numerous alternative therapies are available. A 75-year old patient with the most destructive form of BCC, ulcus terebrans, involving the scalp and invading the frontal bone. We discuss the problems and therapeutic limitations for this unusual BCC variant.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15351870     DOI: 10.1007/s00105-004-0812-6

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  5 in total

1.  Histologic cure of basal cell carcinoma treated with cryosurgery.

Authors:  Theodore J Giuffrida; Gloria Jimenez; Keyvan Nouri
Journal:  J Am Acad Dermatol       Date:  2003-09       Impact factor: 11.527

2.  Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies.

Authors:  John Geisse; Ivor Caro; Jane Lindholm; Loren Golitz; Patti Stampone; Mary Owens
Journal:  J Am Acad Dermatol       Date:  2004-05       Impact factor: 11.527

3.  Polypoid basal cell carcinoma: a new clinicopathological variant.

Authors:  M Megahed
Journal:  Br J Dermatol       Date:  1999-04       Impact factor: 9.302

4.  Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2.

Authors:  Beate Zagrodnik; Werner Kempf; Burkhardt Seifert; Beatrix Müller; Günter Burg; Mirjana Urosevic; Reinhard Dummer
Journal:  Cancer       Date:  2003-12-15       Impact factor: 6.860

5.  [Cutaneous epithelial tumors. Molecular biology and pathogenesis-based therapy].

Authors:  J Reifenberger; M P Schön
Journal:  Hautarzt       Date:  2003-12       Impact factor: 0.751

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.